Anacor Pharmaceuticals to Present at Upcoming Investor Conferences

Before you go, we thought you'd like these...
Before you go close icon

Anacor Pharmaceuticals to Present at Upcoming Investor Conferences

PALO ALTO, Calif.--(BUSINESS WIRE)-- Anacor Pharmaceuticals (NAS: ANAC) announced today that David Perry, the company's Chief Executive Officer, will provide a company overview at the following investor conferences:

  • Wedbush Lifesciences Management Access Conference on Tuesday, August 13, 2013 at 3:40 p.m. ET in New York, New York
  • Canaccord Genuity 33rd Annual Growth Conference on Wednesday, August 14, 2013 at 4:30 p.m. ET in Boston, Massachusetts

The events will be webcast live and may be accessed under "Events and Presentations" on the Investors page of Anacor's website at A replay will also be available for three months following the presentation.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered eight compounds that are currently in development. Its two lead product candidates are topically administered dermatologic compounds — tavaborole, an antifungal for the treatment of onychomycosis, and AN2728, an anti-inflammatory PDE-4 inhibitor for the treatment of atopic dermatitis and psoriasis. In addition to its two lead programs, Anacor has discovered three other wholly-owned clinical product candidates — AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365, an antibiotic for the treatment of infections caused by Gram-negative bacteria. We have also discovered three other compounds that we have out-licensed for further development — two are licensed to Eli Lilly and Company for the treatment of animal health indications and the third compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative, or DNDi, for human African trypanosomiasis (HAT, or sleeping sickness). We also have a pipeline of other internally discovered topical and systemic boron-based compounds in development. For more information, visit

Anacor Pharmaceuticals
DeDe Sheel
Director, Investor Relations and Corporate Communications

KEYWORDS:   United States  North America  California  Massachusetts  New York


The article Anacor Pharmaceuticals to Present at Upcoming Investor Conferences originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

People are Reading